The CD19 Knockout CAL-27 Polyclonal Cells constitute a CRISPR/Cas9-mediated gene-disrupted polyclonal population engineered from the human tongue squamous cell carcinoma cell line CAL-27. This product introduces targeted loss-of-function mutations in the CD19 gene across a mixed cell pool, resulting in abrogation of CD19 protein expression. It is supplied as a polyclonal knockout culture, enabling researchers to interrogate CD19-dependent pathways or to employ the cells as a rigorous negative control in experimental systems where CD19 is not endogenously expressed.
The parental CAL-27 cell line is a well-characterized adherent epithelial line isolated from a human tongue squamous cell carcinoma. It serves as a prominent model for head and neck cancer research, recapitulating key aspects of tumorigenesis, invasive behavior, and response to chemotherapeutic agents. CAL-27 cells display typical squamous epithelial morphology and carry genetic aberrations common in oral malignancies, providing a physiologically relevant platform for studying gene function in upper aerodigestive tract cancers.
CD19 encodes a transmembrane glycoprotein that serves as a crucial co-receptor in B-cell receptor (BCR) signaling, forming a complex with CD21, CD81, and CD225. Upon BCR stimulation, Src-family kinases Lyn and Fyn phosphorylate the cytoplasmic tail of CD19, creating docking sites for the p85 regulatory subunit of PI3K. This event triggers PI3K/AKT and MAPK/ERK signaling cascades, culminating in the activation of transcription factors such as NF-??B. Collectively, these pathways lower the threshold for B-cell activation, enhancing survival, proliferation, and differentiation.
Since CAL-27 cells originate from a non-lymphoid lineage and do not express CD19 endogenously, the CD19 Knockout CAL-27 Polyclonal Cells do not exhibit a loss of native CD19 function; instead, they provide a genetically matched CD19-null background. This makes the model particularly suited as a negative control for CD19-directed studies, including chimeric antigen receptor (CAR) T-cell specificity assays and antibody-based therapeutic evaluations. Moreover, the knockout line serves as a platform for validating CRISPR editing reagents and for scrutinizing off-target genomic modifications in an epithelial cancer context, where CD19 serves no physiological role, thereby reducing confounding biological variables.
Researchers can verify genomic editing by Sanger sequencing or TIDE analysis, and confirm CD19 knockdown at the RNA and protein levels via RT-qPCR, western blotting, and flow cytometry. Standard functional assays??including proliferation, migration, and invasion??allow investigation of any non-canonical CD19 functions in epithelial cancer or assessment of therapeutic specificity. The cells also serve as a control in head and neck cancer immune interaction studies. For further technical support, please contact Ascent Research.
